Recent Updates
Recently added Catalysts
LNTH

Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Second Quarter 2019 Financial Results Worldwide revenue of $85.7 million for the second quarter 2019, representing

Key Takeaway: Lantheus Holdings, Inc. Reports Second Quarter 2019 Financial Results NORTH BILLERICA, Mass., July 25, 2019 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and com

Full Press Release Details

Lantheus Holdings, Inc. Reports Second Quarter 2019 Financial Results
NORTH BILLERICA, Mass., July 25, 2019 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its second quarter ended June 30, 2019.
The Company's worldwide revenue for the second quarter of 2019 totaled $85.7 million, compared with $85.6 million for the second quarter of 2018, representing an increase of 0.2% over the prior year period. Revenue results reflect a mix of strong DEFINITY performance offset by lower TechneLite revenue. Foreign exchange reduced worldwide revenues by $0.2 million or 0.2%.
The Company's second quarter 2019 net income was $6.4 million, or $0.16 per fully diluted share, as compared to $9.7 million, or $0.25 per fully diluted share for the second quarter of 2018, representing a decrease of 35.6% from the prior year period. During the quarter, and contributing to this result, the Company completed an accretive refinancing of its credit facility and expensed $3.2 million, pre-tax, of debt extinguishment costs.
The Company's second quarter 2019 adjusted fully diluted earnings per share were $0.27, as compared to $0.30 for the second quarter of 2018, representing a decrease of 8.3% from the prior year period.
Lastly, Free Cash Flow was $17.6 million, as compared to $14.7 million for the second quarter of 2018, representing an increase of approximately $3.0 million, or 20.3%.
"Our second quarter revenue performance was supported by strong DEFINITY growth in the high teens, offset by multiple molybdenum-99 supplier challenges that impacted our ability to meet total TechneLite demand," said Mary Anne Heino, President and CEO of Lantheus. "Despite these challenges, we delivered both solid earnings per share and Free Cash Flow while continuing to make targeted strategic investments in our business to drive long-term, sustainable growth. While we anticipate additional molybdenum-99 supply challenges in the third quarter, based on the progress our suppliers have made, we now project supply will be stable beginning in the fourth quarter."
The Company offers the following guidance for the third quarter as well as updating its guidance for full year 2019.
Q3 Guidance Issued July 25, 2019
Q3 FY 2019 Revenue Growth (4.4)% - (6.6)%
Q3 FY 2019 Revenue $83 million - $85 million
Q3 FY 2019 Adjusted Fully Diluted EPS $0.18 - $0.20
FY Guidance Updated July 25, 2019
FY 2019 Revenue Growth 0.8% - 1.9%
FY 2019 Revenue $346 million - $350 million
FY 2019 Adjusted Fully Diluted EPS $1.09 - $1.12
Previously stated guidance for full year 2019 was revenue growth of 4.25% to 5.75%, revenue of $358 million to $363 million, and adjusted fully diluted earnings per share of $1.14 to $1.17. Our guidance for Q3 and full year now incorporate the dampening effects of our temporary Moly supply issues that occurred in Q2, continuing into Q3.
On a forward-looking basis, the Company does not provide GAAP income per common share or a reconciliation of adjusted diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company's view that a quantitative reconciliation of adjusted diluted EPS on a forward-looking basis is not available without unreasonable effort.
Internet Posting of Information
The Company routinely posts information that may be important to investors in the "Investors" section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.
Conference Call and Webcast
As previously announced, the Company will host a conference call on Thursday, July 25, 2019 at 8:00 a.m. ET. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 7155758. A live audio webcast of the call also will be available in the Investors section of the Company's website at www.lantheus.com.
A replay of the audio webcast will be available in the Investors section of our website at www.lantheus.com approximately two hours after completion of the call and will be archived for 30 days.
The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.
The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Non-GAAP Financial Measures
The Company uses non-GAAP financial measures, such adjusted net income and its line components; adjusted net income per share - diluted; and free cash flow. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. The measures may
exclude such items which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company's reported results of operations for a period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
This press release includes forward-looking non-GAAP guidance for 2019 adjusted diluted EPS. No reconciliation of this forward-looking non-GAAP guidance was included in this press release because, due to the high variability and difficulty in making accurate forecasts and projections of some of the excluded information and the fact that some of the excluded information is not readily ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measure without unreasonable efforts.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains "forward-looking statements" as defined under U.S. federal securities laws, including statements about our 2019 outlook. Forward-looking statements may be identified by their use of terms such as anticipate, believe, confident, could, estimate, expect, intend, may, plan, predict, project, target, will and other similar terms. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Lantheus Holdings, Inc.
Consolidated Statements of Operations
(in thousands, except per share data - unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Revenues $ 85,705 $ 85,573 $ 172,215 $ 168,203
Cost of goods sold 41,132 41,727 83,558 82,048
Gross profit 44,573 43,846 88,657 86,155
Operating expenses
Sales and marketing 10,948 12,130 21,345 22,770
General and administrative 13,293 11,575 25,882 24,118
Research and development 5,795 4,215 10,724 8,204
Total operating expenses 30,036 27,920 57,951 55,092
Operating income 14,537 15,926 30,706 31,063
Interest expense 4,543 4,298 9,135 8,348
Loss on extinguishment of debt 3,196 - 3,196 -
Other income (1,312 ) (336 ) (2,499 ) (1,256 )
Income before income taxes 8,110 11,964 20,874 23,971
Income tax expense 1,698 2,219 4,513 6,015
Net income $ 6,412 $ 9,745 $ 16,361 $ 17,956
Net income per common share:
Basic $ 0.16 $ 0.25 $ 0.42 $ 0.47
Diluted $ 0.16 $ 0.25 $ 0.41 $ 0.45
Weighted-average common shares outstanding:
Basic 38,972 38,233 38,789 38,060
Diluted 40,239 39,398 40,064 39,468
Lantheus Holdings, Inc.
Consolidated Segment Revenues Analysis
(in thousands - unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 % Change 2019 2018 % Change
United States
DEFINITY $ 53,466 $ 45,103 18.5 % $ 103,182 $ 88,609 16.4 %
TechneLite 16,865 19,343 (12.8 )% 36,923 37,406 (1.3 )%
Other nuclear 9,127 13,031 (30.0 )% 18,651 25,848 (27.8 )%
Rebates and allowances (4,268 ) (3,391 ) 25.9 % (8,132 ) (6,289 ) 29.3 %
Total United States 75,190 74,086 1.5 % 150,624 145,574 3.5 %
International
DEFINITY 1,163 995 16.9 % $ 2,558 $ 2,144 19.3 %
TechneLite 3,241 4,135 (21.6 )% 7,328 7,467 (1.9 )%
Other nuclear 6,119 6,350 (3.6 )% 11,715 13,019 (10.0 )%
Rebates and allowances (8 ) 7 (214.3 )% (10 ) (1 ) 900.0 %
Total International 10,515 11,487 (8.5 )% 21,591 22,629 (4.6 )%
Worldwide
DEFINITY 54,629 46,098 18.5 % 105,740 90,753 16.5 %
TechneLite 20,106 23,478 (14.4 )% 44,251 44,873 (1.4 )%
Other nuclear 15,246 19,381 (21.3 )% 30,366 38,867 (21.9 )%
Rebates and allowances (4,276 ) (3,384 ) 26.4 % (8,142 ) (6,290 ) 29.4 %
Total Revenues $ 85,705 $ 85,573 0.2 % $ 172,215 $ 168,203 2.4 %
Lantheus Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share data - unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Net income $ 6,412 $ 9,745 $ 16,361 $ 17,956
Stock and incentive plan compensation 3,376 2,399 6,157 4,376
Amortization of acquired intangible assets 451 689 902 1,378
Campus consolidation costs - 587 - 1,070
Extinguishment of debt 3,196 - 3,196 -
Strategic collaboration and license costs 300 - 300 -
Income tax effect of non-GAAP adjustments (a) (2,852 ) (1,795 ) (4,795 ) (2,850 )
Adjusted net income $ 10,883 $ 11,625 $ 22,121 $ 21,930
Adjusted net income, as a percentage of revenues 12.7 % 13.6 % 12.8 % 13.0 %
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Net income per share - diluted $ 0.16 $ 0.25 $ 0.41 $ 0.45
Stock and incentive plan compensation 0.08 0.06 0.15 0.11
Amortization of acquired intangible assets 0.01 0.02 0.02 0.04
Campus consolidation costs - 0.02 - 0.03
Extinguishment of debt 0.08 - 0.08 -
Strategic collaboration and license costs 0.01 - 0.01 -
Income tax effect of non-GAAP adjustments (a) (0.07 ) (0.05 ) (0.12 ) (0.07 )
Adjusted net income per share - diluted $ 0.27 $ 0.30 $ 0.55 $ 0.56
Weighted-average common shares outstanding - diluted 40,239 39,398 40,064 39,468
Lantheus Holdings, Inc.
Reconciliation of Free Cash Flow
(in thousands - unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Net cash provided by operating activities $ 21,053 $ 20,276 $ 31,521 $ 19,610
Capital expenditures (3,434 ) (5,626 ) (13,984 ) (7,761 )
Free cash flow $ 17,619 $ 14,650 $ 17,537 $ 11,849
Lantheus Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands - unaudited)
June 30, 2019 December 31, 2018
Assets
Current assets
Cash and cash equivalents $ 56,885 $ 113,401
Accounts receivable, net 45,527 43,753
Inventory 32,414 33,019
Other current assets 5,035 5,242
Total current assets 139,861 195,415
Property, plant and equipment, net 113,117 107,888
Intangibles, net 8,239 9,133
Goodwill 15,714 15,714
Deferred tax assets, net 79,170 81,449
Other long-term assets 34,149 30,232
Total assets $ 390,250 $ 439,831
Liabilities and stockholders' equity
Current liabilities
Current portion of long-term debt and other borrowings $ 10,136 $ 2,750
Accounts payable 17,149 17,955
Accrued expenses and other liabilities 26,072 32,050
Total current liabilities 53,357 52,755
Asset retirement obligations 12,237 11,572
Long-term debt, net and other borrowings 188,706 263,709
Other long-term liabilities 43,703 40,793
Total liabilities 298,003 368,829
Total stockholders' equity 92,247 71,002
Total liabilities and stockholders' equity $ 390,250 $ 439,831
Director, Investor Relations
Director, Corporate Communications
Last updated: Jul 25, 2019